Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720079 | 0.86 | TGFBR1 (0.46) | TGFBR1GSK3AGSK3BMAPK14PREP | |
| SCHEMBL4762611 | 0.85 | TGFBR1 (0.45) | ACKR3TGFBR1TBK1GRIA1SQOR | |
| SCHEMBL4828575 | 0.77 | MAPK14 (0.48) | ACKR3TGFBR1MAPK14 | |
| SCHEMBL4762808 | 0.77 | TGFBR1 (0.48) | TGFBR1GSK3BMAPK14PREPFAP | |
| SCHEMBL4761790 | 0.76 | TGFBR1 (0.49) | TGFBR1ENPP2 | |
| SCHEMBL6002824 | 0.75 | TGFBR1 (0.45) | TGFBR1GSK3AGSK3BMAPK14 | |
| SCHEMBL4761789 | 0.75 | TGFBR1 (0.44) | TGFBR1ENPP2MAPK14 | |
| SCHEMBL4760698 | 0.73 | ACKR3 (0.48) | ACKR3TBK1GRIA1SQORENPP2 | |
| SCHEMBL4722585 | 0.72 | MAPK11 (0.48) | ACKR3ENPP2MAPK14 | |
| SCHEMBL13719563 | 0.72 | ACKR3 (0.58) | ACKR3TBK1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ACKR3 262/4885TGFBR1 572/4885TBK1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.